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Background: Heme oxygenase, cytochrome P450 reductase, and biliverdin reductase are the key enzymes in heme
degradation.
Results: Specific electrostatic and hydrophobic interactions form the binding interface between heme oxygenase and cyto-
chrome P450 reductase.
Conclusion: Heme oxygenase binds cytochrome P450 reductase dynamically and biliverdin reductase very weakly.
Significance: Characterizing interactions among proteins involved in heme degradation are crucial to understanding heme
homeostasis.
Heme oxygenase (HO) catalyzes the rate-limiting step in the
O2-dependent degradation of heme to biliverdin, CO, and iron
with electrons delivered from NADPH via cytochrome P450
reductase (CPR). Biliverdin reductase (BVR) then catalyzes con-
versionof biliverdin to bilirubin.Wedescribemutagenesis com-
bined with kinetic, spectroscopic (fluorescence and NMR),
surface plasmon resonance, cross-linking, gel filtration, and
analytical ultracentrifugation studies aimed at evaluating inter-
actions of HO-2 with CPR and BVR. Based on these results, we
propose a model in which HO-2 and CPR form a dynamic
ensemble of complex(es) that precede formation of the produc-
tive electron transfer complex. The 1H-15N TROSY NMR spec-
trum of HO-2 reveals specific residues, including Leu-201, near
the heme face of HO-2 that are affected by the addition of CPR,
implicating these residues at the HO/CPR interface. Alanine
substitutions at HO-2 residues Leu-201 and Lys-169 cause a
respective 3- and 22-fold increase in Km values for CPR, consis-
tent with a role for these residues in CPR binding. Sedimenta-
tion velocity experiments confirm the transient nature of the
HO-2CPR complex (Kd  15.1 M). Our results also indicate
that HO-2 and BVR form a very weak complex that is only cap-
tured by cross-linking. For example, under conditions where
CPR affects the 1H-15N TROSY NMR spectrum of HO-2, BVR
has no effect. Fluorescence quenching experiments also suggest
that BVR binds HO-2 weakly, if at all, and that the previously
reported high affinity of BVR for HO is artifactual, resulting
from the effects of free heme (dissociated from HO) on BVR
fluorescence.
Precise regulation of heme metabolism is crucial for the cell.
Heme is an active catalyst for generating reactive oxygen spe-
cies by Fenton chemistry and is cytotoxic at elevated levels
(above1M) (1). Heme is also a required prosthetic group for
many proteins involved in electron transfer, oxygen transport,
and redox enzymology (e.g. oxidases) (2). The mammalian
heme degradation pathway consists of two enzymatic steps,
which are mediated by heme oxygenase (HO)4 and biliverdin
reductase (BVR) (Fig. 1). Cytochrome P450 reductase (CPR) is
required as an electron donor for HO catalysis. HO is the only
known catalyst in the mammalian cell that degrades heme
(Reaction 1). HO catalyzes the conversion of heme to biliverdin
in a reaction that requires O2, NADPH, and CPR, which trans-
fers seven electrons as shown in Reaction 1 (3, 4). BVR then
converts biliverdin to bilirubin (Reaction 2), which undergoes
conjugation with glucuronate and is excreted from the body.
heme  7e 3O2¡ biliverdin CO FeII 3H2O
REACTION 1
biliverdin  2e¡ bilirubin
REACTION 2
In addition to protecting the cell from the toxicity of free
heme, the heme degradation pathway generates biologically
important products. TheHOreaction is the only cellular source
of CO, and although high levels of CO are toxic (500 ppm), at
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low levels, CO acts as a signalingmolecule akin toNO (5, 6) and
is cytoprotective (7). The release and recycling of iron from
heme is critical for iron homeostasis as most of the iron
required for the synthesis of new ferroproteins andheme comes
from recycled iron, with less than 3% of the daily iron require-
ment derived from the diet (2, 8). Finally, the HO system pro-
tects cells against oxidative stress, both by controlling free
heme levels and by producing bilirubin, a potent antioxidant
(9–11).
The heme degradation pathway affectsmany areas of cellular
health as follows: heme and iron homeostasis, antioxidant pro-
tection, and gaseous signaling. As such, it is crucial to under-
stand the mechanisms that regulate the activity of HO.
HO exists as twomajor isoforms, HO-1 andHO-2. HO-3 has
also been described; however, it has low catalytic activity, and
its biologic role and relevance are uncertain (12, 13). HO-1 and
HO-2 share a high degree of homology (55% identity and 76%
similarity) and display similar enzymatic activity (14). The two
isoforms, however, have distinct patterns of expression and
regulation. HO-1 is transcriptionally regulated and is expressed
in most tissues, whereas HO-2 is constitutively expressed in a
narrow range of tissues, primarily the brain and testes (15).
Both HOs possess C-terminal membrane-spanning regions
that tether them to the endoplasmic reticulum. However,
because of poor solubility of the full-length protein, most enzy-
matic studies (as those described in this paper) have been con-
ducted with a stable soluble form of HO lacking the C-terminal
region. A major difference between the two HOs is that HO-2
contains three heme regulatory motifs, consisting of a Cys-Pro
dyad, whereas HO-1 completely lacks cysteines (16). Two of
these heme regulatory motifs are at the C terminus of HO-2,
just preceding the membrane-spanning section. When these
are in the dithiol state, the affinity of HO-2 for heme (relative to
the disulfide state) decreases significantly, suggesting that the
heme regulatorymotifs act as a redox switch that controls activ-
ity in response to changes in cellular redox poise (17–19).
Electrons are transferred to HO from NADPH via the 77-
kDa dual flavin enzymeCPR through a pathway that involves its
bound cofactors, FAD and FMN (20–23). In the cell, CPR is
tethered to the endoplasmic reticulum by an N-terminal mem-
brane-spanning region. Protein/protein interactions between
the soluble forms of HO-1 and CPR and between HO-1 and
BVR have been described in vitro (24–27) and are an aspect of
regulation that has not been addressed for HO-2. CPR also
forms electron transfer complexes with the cytochromes P450,
cytochrome b5, cytochrome c, and squalene monooxygenase
(23, 28–31). Interactions with CPR may help define distinct
roles for the HO isoforms. For example, recent reports suggest
that binding of HO-1 and CPR regulates HO-1 nuclear translo-
cation and the transcriptional regulatory response under
hypoxia by stabilizing the endoplasmic reticulum-tethered
form of HO-1 in the cell (32). However, HO-2 appears to
remain stably associated at the endoplasmic reticulum irre-
spective of hypoxic challenge (32).
The complex between the soluble forms of CPR and HO-1
(lacking their membrane-spanning regions) has been charac-
terized by fluorescence quenching (27), surface plasmon reso-
nance (SPR) (24), and acetylation protection assays (25). These
reports provideKd values for theHO-1CPRcomplex that range
from0.4 0.1 to 2.4 0.6M.CPRprotects lysine residues 149
and 153 in HO-1 from chemical modification, suggesting that
these basic residues are at the interface of the HO-1CPR com-
plex (25). Additionally, SPR studies indicate that the K149A
substitution results in an 10-fold increase in Kd for the
HO-1CPRcomplex (24). Although theHO-1CPRcomplex has
been relatively well characterized, the HO-2CPR complex has
not.
BVR catalyzes the second step in heme degradation, i.e. the
reduction of biliverdin to bilirubin (Reaction 2). BVR is a solu-
ble 33-kDa protein that utilizes two electrons from either
NADHorNADPHmaking it unique to have dual cofactor spec-
ificity at distinct pH values (33). In addition to its canonical
enzymatic function, BVR has also been shown to bind and traf-
fic heme to the nucleus where it regulates HO-1 expression
(34–37). Also, BVR is a dual specificity (Ser/Thr and Tyr)
kinase, and as such it is implicated inmitogen-activated protein
kinase (MAPK) cell signaling pathways (38, 39).
Two groups have reported interactions between HO-1 and
BVR via fluorescence quenching studies and SPR (24, 27).
The fluorescence quenching studies suggest a high affinity
HO-1BVR complex (Kd 	 0.2 M) is formed, whereas SPR
studies report that BVR competes with CPR for binding to
HO-1. However, studies that identified the HO-1/CPR inter-
face via lysine acetylation protection assays failed to find evi-
dence for anHO-1/BVR interaction (25). Under single turnover
conditions, the rate-limiting step of the HO-1 reaction is the
release of biliverdin; however, in the presence of BVR, this step
is accelerated (40), which indicates kinetic coupling between
these two enzymes. Thus, although some evidence supports the
formation of a high affinity complex between HO-1 and BVR,
FIGURE 1.Heme degradation pathway. The two enzymatic steps of heme degradationmediated by heme oxygenase and biliverdin reductase. HO converts
heme to biliverdin, and BVR converts biliverdin to bilirubin. The HO reaction requires electrons transferred from NADPH via cytochrome P450 reductase (PDB
1AMO, 2QPP, and 2H63).
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other evidence challenges it. Furthermore, to our knowledge,
the extent to which HO-2 is able to interact with BVR has not
been addressed. Protein/protein interactions between HO and
its reaction partnersmay play an important role in regulating its
various properties, including cellular localization and enzy-
matic activity. Furthermore, given that they exhibit different
modes of transcriptional regulation, HO-1 and constitutive
HO-2 may differ in their affinity for BVR and CPR.
To gain insight into the protein level mode of regulating
HO-2 activity, and to resolve some of the discrepancies related
to measured interactions (or lack thereof) of HO-1 and HO-2
with their binding partners, we have performed nuclear mag-
netic resonance (NMR), kinetic, analytical ultracentrifugation,
gel filtration, cross-linking, SPR, and fluorescence quenching
studies. Our experiments indicate that both HO-1 and HO-2
form complexes with CPR. The interaction between HO-2 and
BVR, however, is weak as compared with CPR, and it can only
be detected by irreversible methods such as cross-linking. Our
results allow us to propose an interface for theHO-2CPR com-
plex near the heme-binding face of HO-2 that includes residues
Leu-201 and Lys-169. Furthermore, our studies demonstrate
that the HO/CPR interface includes both hydrophobic and
charge interactions. Our studies suggest a reinterpretation of
protein/protein interactions in the heme degradation pathway.
We demonstrate that bothHO-1 andHO-2 bindCPR in a tran-
sient electron transfer complex that is required for HO activity.
However, interactions between BVR and HO-2 are weak to
undetectable and may not play a significant role in the physio-
logic context of a cell.
EXPERIMENTAL PROCEDURES
Materials—Ampicillin, isopropyl -D-thiogalactopyrano-
side, kanamycin, NADPH, NADP
, riboflavin, and hemin were
purchased from Sigma. 7-Diethylamino-3-(4-maleimidylphe-
nyl)-4-methylcoumarin (CPM) was purchased fromMolecular
Probes, Inc. (Eugene, OR). OneShot BL21(DE3) chemically
competent cells were purchased from Invitrogen. Nickel-nitri-
lotriacetic acid (NTA) resin was from Qiagen (Valencia, CA).
Glutathione-Sepharose was purchased from GE Healthcare.
Enzymes—Truncated versions of humanHO-1265 containing
residues 1–265, and human HO-2288 containing residues
1–288, and variants of these enzymes, were used in these stud-
ies. These enzymes lack the C-terminal amino acids that com-
prise theirmembrane anchors andwill be referred to asHO-1 and
HO-2. To facilitate expression, solubility, and ease of purification,
HO-1 was cloned into the expression vector pMCSG10 by liga-
tion-independent cloning (41). HO-2 was expressed and purified
from the pET28a(
) vector. HO-1 andHO-2were purified via an
N-terminal His6 tag using Ni-NTA affinity chromatography
according to the manufacturer’s guidelines (Qiagen, Valencia,
CA).
Human CPR66 lacking the N-terminal membrane anchor
was expressed from the pET28a(
) vector and is referred to as
CPR for all studies described herein. CPR was expressed in
BL21(DE3) cells and purified according to published methods
(42). Human BVR was expressed from the pGEX-4T-2 vector
and purified via glutathione-Sepharose affinity resin according
to the manufacturer’s instructions (GE Healthcare).
Unless stated otherwise, affinity purification tags were
removed from all proteins by proteolysis before use in these
experiments. Tobacco etch virus protease (expressed in Esche-
richia coli from pRK793, a derivative of BL21(DE3)-RIL, gener-
ously supplied by Dr. David S. Waugh at the Center for Cancer
Research at NCI, National Institutes of Health) was used for
HO-1, and thrombin was used for HO-2, CPR, and BVR. The
affinity tags were separated from the protein by chromatogra-
phy with the appropriate affinity resin (Ni-NTA for HO-1,
HO-2, and CPR; and glutathione-Sepharose for BVR). All puri-
fication steps were performed at 4 °C.
The cDNA for human full-length HO-1 was graciously sup-
plied by Dr. Ortiz de Montellano (University of California at
San Francisco). The ligation-independent cloning expression
vector pMCSG10 was donated by Dr. William Clay Brown
(University ofMichigan, Ann Arbor). Human full-length HO-2
cDNA in a pGEX-4T-2 vector was generously contributed by
Dr. Mahin D. Maines (University of Rochester, School of Med-
icine, Rochester, NY) and was subcloned into the pET28a(
)
expression vector. CPR was kindly donated by Dr. Bettie Sue
Masters (University of Texas Health Sciences Center, Arling-
ton, TX). The BVR gene was purchased from American Type
Culture Collection (Manassas, VA) and subcloned into the
pGEX-4T-2 plasmid.
Site-directed Mutagenesis of HO-1 and HO-2—Point muta-
tions ofHO-1 andHO-2were constructedusing theQuikChange
site-directed mutagenesis protocol (Stratagene, La Jolla, CA).
Oligonucleotides were synthesized by Integrated DNA Tech-
nologies (Coralville, IA). Positive transformants were enriched
by antibiotic selection and confirmed using sequence analysis.
All of the variants were purified exactly as described above for
the wild type enzymes.
NMR Samples—BL21(DE3) cells containing the pET28a(
)/
HO-2 plasmid were cultured in M9 minimal media with 1.0
g/liter 15NH4Cl (Cambridge Isotopes, Tewksbury, MA) to
achieve 15N labeling of the soluble HO-2 protein. HO-2 was
purified as described above and loaded with heme by titration
of freshly prepared hemin. Hemin stocks were prepared by sol-
ubilizing hemin in 15% dimethyl sulfoxide (DMSO), 0.1 M
NaOH, 50 mM Tris, pH 7.0. Hemin stocks were centrifuged at
17,000  g for 10 min at 4 °C, and the supernatant was then
passed through a 0.22-micron filter (Millipore, Billerica,MA) to
remove insoluble matter. Hemin concentration was deter-
mined using an 385 nm of 58.44 mM1 (43). HO-2 was loaded
with hemin by titrating small amounts of hemin and monitor-
ing the Soret peak at 404 nm until saturating levels of heme
binding were achieved. NMR samples were prepared with 150
M heme-bound HO-2 in 50 mM Tris-HCl, pH 7.0, 50 mM KCl
with 10% D2O in a total volume of 350 l and placed in a Shi-
gemi NMR tube. Experiments testing the ability of CPR or BVR
to bindHO-2were conducted with 150MHO-2 and the bind-
ing partner (BVR or CPR) at the indicated concentration.
1H-15N apoHO-2 NMR TROSY samples were prepared
identically to those described for hHO-2; however, heme was
absent from the samples.
For perdeuterated 15N-HO-2, samples were prepared as
described above; however, BL21(DE3) cells were grown and
induced in 2H2O/M9 minimal media. Electrospray ionization
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mass spectrometry analysis revealed label incorporation to be
99.8%.
1H-15N TROSY NMR Measurements—Two-dimensional
1H-15N HSQC TROSY spectra were acquired on an Agilent/
Varian 800 MHz spectrometer equipped with a triple reso-
nance gradient (PFG) cryoprobe operating at 30 °C. Spectra
were acquired using an array of 2404 300 complex points and
with the spectral widths of 12019.2 and 2999.9 Hz for 1H and
15N, respectively. All spectra were processed with NMRPipe
software (44) and visualized using Sparky 3.114 (45). Intensity
analysis was conducted as described (46); the peak heights of
chemical shifts were derived from Sparky and used to calculate
the ratio of resonance height for the 1H-15N HO-2 spectrum
with and without CPR or BVR. The chemical shift perturbation
(CSP) for the assigned cross-peaks wasmeasured between the 0
M CPR spectrum and the 75 or 150 M CPR spectrum for the
perdeuterated 15N-hHO-2TROSY spectrum. CSPswere calcu-
lated from the square root of the sum of the squared N1H and
15N CSPs for each assigned cross-peak.
NMR Relaxation—The experiments for studying the 15N
NMR relaxation of HO-2 were carried out using a 40 MHO-2
sample thatwas 15N-labeled in 50mMTris-HCl, 50mMKCl, pH
7.0, and recorded at 30 °C on a Agilent/Varian 800 MHz NMR
system, using a cryoprobe.
One-dimensional versions of the standard 15N R1 and 15N R2
HSQC experiments (with cross-correlation, but with without
Rex suppression) were carried out (47). In these experiments,
amide proton magnetization is transferred to the amide 15N,
where it is allowed to decay according to 15NR1 or R2 relaxation
mechanisms and transferred back to the amide proton for
observation. R2 relaxation is faster for larger than for smaller
molecules; R1 relaxation is slower for larger than for smaller
molecules. From the ratio, onemay calculate the rotational cor-
relation time. For spherical, rigid proteins, the rotational corre-
lation time is proportional to the molecular weight. The data
were processed in NMRpipe and exported in text format using
the Pipe2txt.tcl routine. The data were then imported into
Microsoft Excel. For each spectrum, the ranges 8.7–9.0 ppm
(structured core residues) were integrated, and the data were fit
to a single exponential decay curve using in-house written non-
linear least square fit code with jackknife error estimation (48).
Steady-state Kinetic Analysis of HO-1, HO-2, and Variants—
TheHOenzymatic assaywasmodified frommethods described
previously (49, 50). Recent studies establish that catalase
enhances the linearity of the membrane-bound HO-1-cata-
lyzed reaction (50). In our soluble system, we found a similar
benefit of catalase for both HO-1 and HO-2 and therefore
included it in the enzymatic assays. The 200-l reaction con-
tained 0.1 MHO, 15 M heme, 0.35 M BVR, 0.25 g/l BSA,
20 units/l catalase, and varying concentrations of CPR in reac-
tion buffer (50 mM Tris-HCl, pH 8.0, 50 mM KCl). The reaction
was incubated at 37 °C for 2 min and then initiated with the
addition of 8 l of 10 mM NADPH. Activity was monitored
using a Shimadzu UV-2600 spectrophotometer by following
the increase in bilirubin absorbance at 468 nm. The difference
extinction coefficient between heme and bilirubin at 468 nm of
43 mM1 cm1 was used.
Size Exclusion Chromatography—For gel filtration experi-
ments, proteins were dialyzed into buffer containing 50 mM
Tris-HCl, pH 7.0, 50 mM KCl. After recovery from the dialysis
tubing, samples were prepared with 50M of the indicated pro-
tein, 150 M heme, and 150 M NADP
. Gel filtration was
conducted with a Shimadzu HPLC with an LC-10AT pump
system using a Shodex KW-803 column (Shodex, Torrance,
CA). The column was calibrated using gel filtration standards
(Bio-Rad), and the void volumewas determined using blue dex-
tran (2000 kDa, Sigma).
Surface Plasmon Resonance with HO and CPR—SPR binding
experimentswere conducted using a BIAcore 2000 (GEHealth-
care) at 25 °C in 50 mM Tris, pH 7.0, 50 mM KCl with 0.005%
surfactant p20. HO-1 or HO-2 was immobilized directly to the
dextran matrix of a research grade CM5 sensor chip by amine
coupling according to the manufacturer’s instructions (GE
Healthcare). The sensor chip surface was activated with NHS/
EDC for 7 min. Immobilized proteins were diluted to 0.001
g/l with 10mM sodium acetate, pH 4.5, and injected over the
sensor chip surface. Tominimize nonspecific binding andmass
transfer, the immobilization levels were kept below 1000
response units. HO-1 and HO-2 were immobilized to 900 and
300 response units, respectively.
For kinetic analysis of CPR andHO, 45l of varying concen-
trations of CPR were injected at a flow rate of 20 l/min. Chip
regeneration was conducted with a 5-l injection of 0.5 mM
NaCl. A blank reference cell was subtracted from the experi-
mental data. To determine kinetic parameters, three indepen-
dent experiments were initially analyzed using BIAevaluation
software (GE Healthcare) and fit to a 1:1 Langmuir binding
model or a bivalent analyte model. Because these models fit the
data poorly, the association phase of CPR binding to HO was
analyzed using single exponential fits (GraphPad 6.0). Kinetic
constants were determined from the linear regression of kobs
values plotted against CPR concentration.
For experiments with immobilized CPR, human CPR was
immobilized to the CM5 chip according to previously described
methods for immobilization of rat CPR (24). Briefly, CPR was
immobilized via thiol groups of cysteine residues with the cou-
pling reagent 2-(2-pyridinyldithio)ethaneamine). To stabilize
the enzyme and protect residues near theNADPH-binding site,
NADPH was included during the immobilization of CPR. CPR
was immobilized to 2000 response units. Others have
reported that modification of CPR by 2-(2-pyridinyldithio)
ethaneamine) does not affect enzyme activity (24). Binding
analysis with immobilized CPR was performed identically to
those described above, with freshly prepared hemin as the sol-
uble analyte.
SedimentationVelocityAnalysis—Binding interactionsbetween
HO-2 and CPRwere analyzed by sedimentation velocity exper-
iments using a method described previously (51). Sedimenta-
tion velocity experiments were performed on an Optima XL-I
analytical ultracentrifuge (Beckman Coulter, Inc.) equipped
with an eight-hole An50Ti rotor. Prior to analysis, HO-2 and
CPR were dialyzed against 50 mM Tris, pH 8.0, containing 150
mM NaCl. CPR (20.5 M) was then mixed with increasing con-
centrations of HO-2 (0–55 M), and the resulting protein mix-
tures (400 l) were loaded into the sample compartment of a
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double-sector cell. The reference compartment was filled with
430 l of the dialysate buffer. Sample cells were then incubated
at 20 °C in the rotor chamber for 2 h under vacuum. After 2 h of
incubation, samples were sedimented at 40,000 rpm. A total of
180 absorbance scans (450 nm) at 3-min intervals were col-
lected. Absorbance values ranged from 0.2 to 0.8 for the differ-
ent samples. The data were analyzed by SEDFIT version 10.58d
(52) using the continuous c(s) distribution model and allowing
the frictional ratio to float. CPR-/HO-2 interactions weremon-
itored by integrating the c(s) distribution between 4 and 7 S to
determine the weight-average s value of the new observed
boundary component (51). A Kd value for the CPRHO-2 com-
plex was estimated by plotting the weight-average s value as a
function of HO-2 and fitting the data to a single-site binding
isotherm.
Chemical Cross-linking—The reducible, heterobifunctional
cross-linker (succinimidyl 6-(3-[2-pyridyldithio]-propionami-
do)hexanoate) (LC-SPDP) was used in a two-step reaction
according to the manufacturer’s instructions (Thermo Scienti-
fic/Pierce). HO-1 or HO-2 was activated as follows. A fresh 3
mM solution of LC-SPDP was prepared in DMSO. 10 MHO-1
or HO-2 was prepared in conjugation buffer (0.1 MHEPES), pH
7.5, 30 mM EDTA, 150 mM NaCl and incubated with 0.1 mM
LC-SPDP for 30 min at room temperature. Unconjugated
cross-linker was then removed by three rounds of buffer
exchange using 10,000molecular weight cutoff Amiconmicro-
concentrators (Millipore, Billerica, MA). 10 M BVR, CPR, or
RNasewas then added to the activated protein, and the reaction
was incubated at 4 °C overnight. Cross-linking reactions were
analyzed by 5–15% gradient sodium SDS-PAGE (Bio-Rad) and
visualized by staining the gel with Coomassie Blue (53).
Co-purification of BVR with HO-2—For the co-purification
of BVR with HO-2, the cross-linking reaction was performed
exactly as described above; however, HO-2 contained anN-ter-
minal His6 tag (hisHO-2) that was absent in the other reactions.
By SDS-PAGE, the cross-linked products of the reaction con-
taining hisHO-2 and BVR migrated to identical positions as
those in which the His6 tag had been removed from HO-2.
Samples of hisHO-2 alone, BVR alone, or cross-linked hisHO-
2/BVR were incubated with 100 l of Ni-NTA resin (50%
slurry) for 2 h at 4 °C. Samples were rotated on a Boekel variable
speed mini-tube rotator (Fisher). Affinity resin and associated
proteins were harvested by centrifugation for 5 min at a setting
of 2400  g at 4 °C with an accuSpin Micro 17R refrigerated
microcentrifuge (Fisher) and washed three times with 1 ml of
wash buffer (50 mM Tris-HCl, pH 8.0, 30 mM NaCl, 20 mM
imidazole). Protein bound to the resin was eluted with 50 mM
Tris-HCl, pH 8.0, 30 mM NaCl, 300 mM imidazole. Eluted frac-
tionswere boiled for 5min in SDS-PAGE loading buffer (50mM
Tris-HCl, pH 6.8, 2% (w/v) SDS, 0.1% (w/v) bromphenol blue,
10% (v/v) glycerol, and 100mM dithiothreitol) and separated by
10% SDS-PAGE (53). Proteins were then transferred to a nitro-
cellulose membrane and detected using antibodies against
either HO-2 (18) or BVR (Abcam, Cambridge, MA).
Modification of BVR with CPM—Human BVR was modified
with 7-diethylamino-3-(4-maleimidylphenyl)-4-methylcou-
marin (CPM) according to methods used to modify rat BVR
(27). A 20 mM solution of CPM was prepared in dimethyl sulf-
oxide. 10MBVRwith 1mMNADPHwas incubated in the dark
with 100MCPMat 4 °C for 16 h. FreeCPMwas removedusing
a PD-10 desalting column (Amersham Biosciences). Labeled
BVR was then frozen and stored in the dark at 80 °C. BVR-
CPM was analyzed by LC MS/MS to determine the location of
the CPMmodification.
Fluorescence Resonance Energy Transfer (FRET) Analysis of
the Interaction of HO-1 or HO-2 with BVR—FRET experiments
to examine HO-1 or HO-2 binding to human BVR were con-
ducted according to previously described methods for rat BVR
(27). Briefly, because the UV-visible spectra of heme-bound
HO-1 andHO-2 overlap the fluorescence emission spectrum
of the fluorescent probe CPM, binding of heme-bound HO
should result in fluorescence quenching of BVR-CPM. BVR-
CPM (0.05 M) was titrated with various concentrations of
heme-bound HO-1, heme-bound HO-2, or heme, and fluo-
rescence wasmonitored at 450 nmwith excitation at 350 nm.
These experiments were performed in 0.1 M potassium
phosphate buffer at pH 7.4 on a Shimadzu FR-5301PC
spectrofluorophotometer.
Heme Binding BVR by Optical Absorbance—To obtain the
absorbance spectrum of heme-BVR, the difference spectra
between 350 and 700nmwere recorded for 2.5MBVRwith 2.0
M heme, whereas the reference cuvette contained 2.5MBVR
alone. To determine binding affinity of heme for BVR, 10 M
hemin was titrated with increasing amounts of BVR (0.5–5.0
M) with 10 M heme alone in the reference cuvette. Absor-
bance at 415 versus BVR concentration was fit to a single site
binding model using GraphPad Prism 6.0. To assess the ability
of BVR to bind heme from hHO-2, 5 M of hHO-2 was incu-
bated with varying concentrations of BVR (1.0–20.0 M), and
the absorbance spectra from 250 to 700 nm was collected, with
the reference cuvette containing 5 M hHO-2. hHO-2 was pre-
pared by incubating apoHO-2 with a 5-fold excess of freshly
prepared hemin for 1 h at 4 °C. Unbound heme was removed
using a PD10 desalting column according to themanufacturer’s
instructions (GE Healthcare). For all experiments fresh hemin
was used andwas prepared as described above. All spectra were
collected on a Shimadzu UV-2600 spectrophotometer.
RESULTS
Various forms of HO and CPR lacking their transmembrane
segments were used in these studies. These are HO-1(1–265)
containing residues 1–265, HO-2(1–288), and CPR(66–680).
For clarity, these proteins will be referred to simply as HO-1,
HO-2, or CPR. In experiments that use heme-bound HO, we
refer to the protein as hHO-1 or hHO-2.
NMR Analysis of the Interaction between hHO-2 and CPR—
NMR is a highly sensitive method to probe protein/protein
interactions. Binding of an NMR-silent protein to an NMR-
visible protein can perturb the spectrum in several ways; it can
change the chemical shift, alter the line width of a resonance, or
affect both chemical shift and line width. If resonances within
the NMR spectrum have been assigned, these spectral changes
can provide residue-specific information regarding the inter-
face between the two proteins.
We recently assigned 70% of the backbone chemical shifts of
the hHO-2 (heme-bound) NMR spectrum by three-dimen-
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sional NMR experiments using a highly concentrated sample (1
mM).5 To avoid potential nonspecific interaction effects that
could arise with highly concentrated protein, in the binding
studies described here, we used 150 M 15N hHO-2 samples.
Because large proteins such as HO-2 (33 kDa) tend to exhibit
faster transverse relaxation that reduces signal intensity of the
NMR spectrum, we utilized transverse relaxation-optimized
spectroscopy (TROSY). TROSY is a method that reduces the
1H and 15N resonance line widths to enhance the spectra of
larger proteins (30 kDa) (54). By applyingTROSY,we observe
211 cross-peaks in the 1H-15N TROSY spectrum of perdeuter-
ated 15N-hHO-2, which accounts for resonances arising from
70% of the hHO-2 residues (Fig. 2). The hHO-2 spectrum
consists of resonances arising from both ordered and disor-
dered regions of the protein. Amide proton resonances arising
from disordered regions of HO-2 occur in the 7.7–8.6 ppm
range, which has a high density of overlapping peaks character-
istic of poorly structured regions (46). This region of the spec-
trum corresponds to the flexible N- and C-terminal domains of
hHO-2 residues 1–28 and 243–288. The well dispersed peaks
outside of the disordered region arise from the core of hHO-2,
as highlighted by the annotated spectra (Fig. 2).5 Also, in the
crystal structure ofHO-2 (PDB2QPP), only the catalytic core of
the protein (residues 29–242) is visible, and both the N and C
termini are not observed, further supporting the flexibility of
the N and C termini (55).
To probe the interface between hHO-2 and CPR, we col-
lected the spectrum of perdeuterated 15N-hHO-2 in the pres-
ence or absence of natural abundance CPR (lacking any label).
As noted above, we used a lower concentration of hHO-2 (150
M) thanwas used earlier tomake the assignments tominimize
the potential for nonspecific effects such as aggregation. We
overlaid the assigned HO-2 spectrum with that collected in the
binding studies to determine assignments for the spectrum in
the binding studies. Using this method,50% of the 288 HO-2
residues in the binding study could be assigned. Analysis of the
HO-2 spectrum described below will focus on the assigned
region of the protein.
We measured the chemical shift and peak height for reso-
nances in the hHO-2 TROSY spectrum in the presence and
absence of CPR. To identify hHO-2 residues that are affected by
CPR, we compared the 1H-15N TROSY spectrum of hHO-2 in
the presence of equimolar unlabeled CPR with that of hHO-2
alone. The addition of CPR to hHO-2 causes changes in hHO-2
chemical shifts and also decreases in peak intensities for a num-
ber of hHO-2 residues (Fig. 2). This peak intensity loss is con-
sistent with an increase in molecular weight and concomitant
reduction of TROSY intensity that we would expect to occur as
hHO-2 molecular weight increases with the binding of a
70-kDa protein such as CPR (46, 56).5 I. Bagai, S. W. Ragsdale, and E. R. P. Zuiderweg, manuscript in preparation.
FIGURE 2.NMR analysis of CPR binding hHO-2. 1H-15N TROSY spectra of 150M perdeuterated 15N-hHO-2 collected in the absence (black) or presence (red)
of equimolar CPR.
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The addition of CPR to hHO-2 also results in CSPs for some
hHO-2 cross-peaks (Fig. 3). This demonstrates that the kinetics
of binding is in the fast or intermediate fast exchange for which
the resonance position iobs of a certain residue i is given by
Equation 1 (57),
 i
obs ffreei
free fboundi
bound (Eq. 1)
where ffree and fbound are the molar fractions of free and com-
plexedHO-2, andwhereifree andibound are the chemical shifts
in radians of that resonance in those states. Equation 1 holds for
both 1H and 15N dimensions in the TROSY spectrum.
To quantify CSPs, the 1H and 15N chemical shift difference
was calculated by comparing the chemical shifts of hHO-2
alone with those of CPR. The combined 15N/NH chemical shift
change was calculated as the chemical shift change vector as
described under “Experimental Procedures.”Of the 47 assigned
cross-peaks in the N and C termini, none exhibit significant
CSPs with the addition of equimolar CPR; however, 28 residues
from the HO-2 core exhibit significant CSPs (Fig. 4). Mapping
the residues with significant CSPs onto the hHO-2 crystal
structure highlights contiguous patches of residues on HO-2
that are likely involved in binding CPR or experience allosteric
effects upon CPR binding (Fig. 5). Equally important, there are
also many assigned resonances that do not shift, and they also
form contiguous patches.
For the range 0.1 ffree or fbound 0.9, the line width, LWiobs,
for a resonance i in the fast/intermediate exchange regime is
given by Equation 2 (57).
LWi
obs ffreeLWi
free fboundLWi
bound ffreefbound
(i
freei
bound)2
1 fbound/ffreekoff
(Eq. 2)
Here, the first two terms represent the increase in line width
due to a change in the time-averaged molecular weight of
HO-2, although the latter term, called exchange broadening, is
excess broadening due to the kinetics of binding.
The increase in line width causes a loss in TROSY cross-peak
height by two processes as follows: the first is a linear effect and
occurs because a broader line in the spectrum has a lower peak
height; the second is a strongly nonlinear effect due to a
decrease in the coherence transfer efficiencies in the TROSY
experiment itself. For large proteins that bind to other large
proteins, the second effect is dominant.
To quantify the peak intensity loss in the hHO-2 spectrum
upon CPR binding, the peak intensity ratio was determined by
dividing the cross-peak intensity in the presence of CPR by the
cross-peak intensity from the hHO-2 alone spectrum (
CPR/
CPR, Fig. 6). A ratio of 1 indicates no effect, although a
decreased ratio indicates line broadening for that resonance.
Cross-peaks derived from residues located at theHO-2NandC
termini (residues 1–28 and 243–288) are largely unaffected by
the addition of equimolar CPR; of the 47 assigned cross-peaks,
only four exhibit chemical shift intensity ratios of less than 0.8
(Gly-20, Ala-245, and Glu-247). This is in contrast to the 96
assigned cross-peaks located at the core of HO-2 (residues
29–242); 88 resonances exhibit an intensity ratio of less than
0.8, and 23 have disappeared likely due to broadening beyond
detection (Fig. 6). Mapping the intensity ratios onto the hHO-2
crystal structure shows the residues that are most strongly
affected by CPR are on the heme binding face of hHO-2 (in
which the heme binding pocket and surrounding residues are
visible), although residues on the opposite face (180° rotation)
of hHO-2 are less affected (Fig. 7).
The interaction areas determined from intensity changes
(Fig. 5) and chemical shift changes (Fig. 7) do overlap in general,
FIGURE 3. Effect of CPR on hHO-2 chemical shifts. Detail of the 1H-15N hHO-2 spectrum with 0, 75, or 150 M CPR (black, blue, and red, respectively)
highlighting cross-peaks that experience significant perturbations of the chemical shift or significant intensity loss. Glu-182 and Asp-210 show highly signif-
icant change in chemical shifts, although Leu-81 is broadened beyond detectionwith the addition of CPR. x represents the center of the indicated cross-peak.
Highly significant changes in CSP are greater than two standard deviations from the mean CSP for assigned residues.
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suggesting the main binding area is identified by both observ-
ables. However, the intensity changes and chemical shifts do
not correlate per residue. The most compelling case occurs
for the resonance of Leu-201, which completely disappears
although it does not shift. As discussed below, this discrepancy
indicates a complex binding mechanism.
Titration of CPR into hHO-2 by NMR—If the effects of CPR
on the hHO-2 spectrum are due to CPR binding, changes
induced by CPR should be titratable. Thus, additional experi-
ments were conducted with 50, 150, 200, and 300 M CPR, and
the resonance height ratio was calculated as described above
(Figs. 8 and 9). Under these conditions, using hHO-2 that was
not perdeuterated, we observed 165 cross-peaks in the 1H-15N
hHO-2 spectrum, which accounts for resonances arising from
60%of the hHO-2 residues. Comparison of these spectrawith
the assigned spectrum allows for assignment of 36% of 288
HO-2 residues (Fig. 9).
To quantify the effects of CPR on hHO-2 residues, we com-
pared the 1H-15N TROSY spectrum of hHO-2 in the presence
of CPR to that of hHO-2 alone. Although the addition of CPR to
hHO-2 does not cause observable changes in hHO-2 chemical
shifts in the TROSY spectrum for non-perdeuterated hHO-2, a
decrease in peak intensity for a number of hHO-2 residues pro-
portional to the concentration of CPR is observed (Fig. 9).
Although titratable changes in the HO-2 spectrum could con-
ceivably result from CPR-dependent catalytic activity of HO-2,
this is unlikely to be the cause of the observed intensity changes
because NADPH is not present in the NMR experiment and
HO-2 is inactive in its absence. Furthermore, CPR causes sim-
ilar peak height reduction for the apoHO-2 spectrum, here sub-
FIGURE 4. Effect of CPR on hHO-2 chemical shifts.Histogram bars represent the combined 15N/NH chemical shift perturbation (CSP) for assigned residues in
the hHO-2 spectrum in the presence of 75 or 150M CPR (white or gray, respectively). The CSP for the assigned cross-peaks, measured between the 0M CPR
spectrum and the 75 or 150 M CPR spectrum, was calculated from the square root of the sum of the squared N1H and 15N CSPs. Cross-peaks that have
broadened beyond detection with the addition of CPR are shown as black bars of uniform height. Dotted lines indicate CSPs that are significant (1 standard
deviation from the mean) or very significant (2 standard deviations from the mean). Bars with gray labels represent resonances that are unassigned, and
assigned residues are in black.
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strate and reducing equivalents are both absent, preventing any
catalytic turnover.
Of the assigned residues in the hHO-2 spectrum, the residue
that is most affected by the addition of equimolar concentra-
tions of CPR is Leu-201. Glu-107, Ala-208, Leu-209, Leu-211,
and Leu-33 are also strongly affected. Although in our 150 M
NMR sample we do not have consecutive assignments for these
residues, in the more concentrated multidimensional experi-
ments used for assigning the hHO-2 spectrum Leu-201, Ala-
208, Leu-209, and Leu-211 are part of a consecutively assigned
region Glu-190–Asn-212. Leu-33 is part of a consecutively
assigned region from Arg-29–Leu-37 and Glu-107 is part of a
consecutively assigned region from Glu-107–Leu-109, so the
assignments are quite secure.
We also conducted 15N T2 and T1 relaxation experiments to
estimate the molecular mass of hHO-2 under the NMR condi-
tions. The rotational correlation time of a protein is linearly
related to its molecular weight; therefore, 15N spin relaxation
rates can be used to determine the molecular weight of a pro-
tein in solution (58). The molecular mass estimate for the
hHO-2 core was found to be 55 kDa. The mass of monomeric
hHO-2(1–288) is 33 kDa and that of the hHO-2 core (29–242)
is 25 kDa. Thus, the NMR relaxation experiments indicate that
hHO-2 is a dimer under the present conditions (40 M
protein).
NMR Analysis of the Interaction between apoHO-2 and
CPR—To test the ability of CPR to bind apoHO-2, the 1H-15N
spectrum of 500M non-perdeuterated 15N-apoHO-2 was col-
lected in the presence or absence of 100 M CPR, as described
for hHO-2. The addition of CPR to apoHO-2 causes a loss of
intensity for apoHO-2 cross-peaks similar to what is observed
in the hHO-2 spectrum (Fig. 10). In the apoHO-2 spectrum, 121
distinct cross-peaks are visible, representing 40% of HO-2
residues. Although assignments for the apoHO-2 spectrum
have not been determined, changes in chemical shift intensity
were quantified by calculating the chemical shift height ratio
(
CPR/CPR) for each of the cross-peaks. Of the 121 distinct
cross-peaks analyzed in the apoHO-2 spectrum, 19 exhibit a
chemical shift height ratio of less than 0.8, indicating a loss of
cross-peak height for the corresponding HO-2 residues.
Changes in chemical shift are not observed for any cross-peaks
in the non-perdeuterated spectra. These data indicate that CPR
is capable of binding apoHO-2 as well as hHO-2.
Assignments have not been independently determined for
the apoHO-2 TROSY spectrum, and the spectrum is distinct
from that of hHO-2 (Fig. 11). However, some isolated cross-
peaks of the hHO-2 spectrum have identical chemical shifts as
in the apoHO-2 spectrum, allowing for a reasonable assign-
ment of the apoHO-2 cross-peak from the hHO-2 spectrum,
notably Leu-201 (Fig. 11). Strikingly, of the 121 cross-peaks
analyzed, the cross-peak at the location of Leu-201 in the
apoHO-2 spectrum is themost sensitive to the addition of CPR,
similar to what was observed for the hHO-2 spectrum.
Steady-state Kinetic Analysis of HO-1 and HO-2 Mutants—
Residues that exhibit large changes in the hHO-2 NMR spec-
trum upon binding CPR could be present at the interface of
HO-2 and CPR, or alternatively, they could change their chem-
ical environment due to long range conformational changes in
HO-2 induced by CPR binding at a distant site. Based on the
hypothesis that mutation of residues at the HO-2/CPR inter-
face would lead to an increase in Kd values for the HO-2CPR
complex and, thus, an increasedKm value forCPR,we tested the
effect of alanine substitutions on steady-state kinetic parame-
ters for Leu-201 and Lys-169, which were expected to exhibit
higher Km values, and Arg-87, which was used as a control. If a
residue exhibits changes in the NMR spectrum by indirect
effects (e.g. due to a conformational change), making a conserv-
ative mutation of that residue is unlikely to affect the Kd or Km
values. Also, we note that HO-2 is likely a homodimer in the
NMR binding studies. If a resonance is affected by a change in
HO-2 dimerization state, a mutation of that residue would be
unlikely to affect the kinetic parameters of HO-2 and CPR.
Alanine substitution of theHO-2 residuewith the cross-peak
intensity that is most strongly affected by equimolar CPR in the
non-perdeuterated NMR binding studies (Fig. 9), L201A,
results in a 3-fold increase in the Km for CPR and no change in
kcat compared with wild type protein (Fig. 12B and Table 1).
However, the R87A variant of HO-2, whose NMR cross-peak
height is not strongly affected by the addition of CPR, exhibits
no change in the kcat or Km values for CPR (Fig. 12B and Table
1). These results are consistent with a role for Leu-201 at the
binding interface for CPR.
We also studied the K169A variant of HO-2 because alanine
substitution of Lys-149, the analogous residue in HO-1, exhib-
its a 7–10-fold increase in the Kd value of the HO-1CPR com-
plex (24, 27). We observe an20-fold increase in the Km value
of the K169A variant of HO-2 for CPR (Fig. 12B, Table 1) and a
40-fold increase in the Km value for the K149A variant of HO-1
(Fig. 12A and Table 1). These results indicate that this lysine
residue of HO-2 and HO-1 is involved in binding CPR.
Gel Filtration Analysis of the Binding of hHO-1, hHO-2, and
CPR—In an attempt to observe the complex between CPR and
HO-2 (and HO-1) by other methods, we performed gel filtra-
tion experiments. Kd values ranging from 0.5 to 2.0 M have
been reported for hHO-1 and CPR, and NADP
 is reported to
FIGURE 5. CPR-induced CSPs on the hHO-2 spectrum mapped onto the
crystal structure. The effect of 75 or 150 M CPR (A and B, respectively) on
hHO-2 CSPs as determined in Fig. 4 wasmapped onto the crystal structure of
hHO-2 (PDB 2QPP). The color of the residue reflects the degree of CSP effect
by CPR. Red indicates residues with highly significant CSPs (more than two
standard deviations from the mean); orange indicates residues with signifi-
cant CSPs (at least one standard deviation from the mean); blue indicates
residues with no significant CSP;white indicates residues that are broadened
beyond detection; gray indicates residues that are unassigned.
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enhance binding (24, 27). We performed gel filtration experi-
ments with 50 M HO-1 or HO-2 and equimolar CPR in the
presence of 150MNADP
 and 150Mheme. For comparison,
the elution of the individual proteins (HO-1,HO-2, andCPR) in
the presence of heme and NADP
 was also determined.
Because heme orNADP
 could affect themigration of the indi-
vidual proteins, they were included in 3-fold excess in all
samples.
By gel filtration analyses, we did not observe any evidence for
a complex between CPR and either hHO-1 or hHO-2 (Fig. 13
and Table 2). CPR migrates at position 1 (70 kDa) in the
absence (dashed line) or presence (red lines) of hHO-1 or
hHO-2 (Fig. 13). Peak 2, which marks the migration of hHO-2
or hHO-1, corresponds to 60 and 44 kDa, respectively, and
shows up as a shoulder in Fig. 8A in the HO-1/CPR sample.
Consistent with the NMR relaxation studies, these results sug-
gest that hHO-2 exists as a homodimer under these conditions.
The difference in apparent mass between HO-1 and CPR is
greater than that between HO-2 and CPR; therefore, peaks 1
and 2 are slightly separated in Fig. 13A and are overlapped in
Fig. 13B. The elution profiles of CPR were unaffected by incu-
bation with either HO-1 or HO-2; for example, a CPRHO-2
complex, which would have eluted at a position corresponding
to 100 kDa, was not observed. Others have also failed to
observe a complex between wild type HO-1 and CPR by gel
filtration (26). TheHOCPR complex is undetected under these
conditions, suggesting that the complex is weak and/or highly
transient, consistent with the NMR and steady-state kinetic
studies.
Binding of CPR to HO-1 or HO-2 by Surface Plasmon Reso-
nance (SPR)—We also attempted to quantify CPR binding to
HO-1 and HO-2 using SPR, with HO-1 or HO-2 immobilized
FIGURE 6. Effect of CPRonperdeuterated hHO-2 chemical shift intensities.Histogrambars represent the ratio of peak height in the absence or presence of
CPR (
CPR/CPR). Ratios with 75 and 150 M CPR are shown (white and gray, respectively). A ratio of 1 (dotted line) indicates no change for that residue.
Negative bars represent cross-peaks that arebroadenedbeyonddetectionwith the additionofCPR.Bars that are absent represent residues that areunassigned
in the spectrum.
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on the dextran surface of the SPR chip through amine chemis-
try (Fig. 14). Representative association and dissociation curves
with various concentrations of CPR (1.25–20 M) are shown in
Fig. 14A. The SPR sensorgrams show CPR-dependent associa-
tion and CPR-independent dissociation phases, clearly demon-
strating that CPR binds to both HO-1 and HO-2. To avoid
potential artifacts, these experiments were performed in the
absence of heme because heme itself produced a strong “bind-
ing” response (Fig. 14E). Use of the apoproteins is justified by
our NMR experiments (above) using apoHO-2 and CPR, which
clearly demonstrate that CPR can bind both apoHO-2 and
hHO-2.
To derive binding kinetic constants from the SPR sensor-
grams, the association and dissociation phases were fit individ-
ually because simultaneous global fitting analysis of CPR asso-
ciation and dissociation curves using the 1:1 Langmuir model
(BIAevaluation) produces a poor fit to the data. Single exponen-
tial fits of the association phase (GraphPad Prism6) of CPR and
HO-1 or HO-2 were used to determine kon values (0.0010 
0.0002 and 0.0014 0.0002 s1 M1) and koff values (0.020
0.003 and 0.0230  0.0003 s1) for CPR binding to HO-1 or
HO-2, respectively (Fig. 14, B and C). From these kon and koff
values, the Kd values of 20.5  7.6 and 16.7  2.5 M were
determined for CPR and HO-1 or HO-2, respectively, indicat-
ing that these proteins form relatively weak (transient) com-
plexes. Biexponential fits of the dissociation curves (Fig. 14D)
indicate a fast and slow dissociation phase, with kfast values in
reasonable agreement with the values determined by linear
regression analysis of the binding data (kfast 	 0.026  0.002
and 0.035  0.008 s1; kslow 	 0.0030  0.0015 and 0.0025 
0.0005 s1 for HO-1 and HO-2, respectively).
Sedimentation Velocity Analysis of HO-2 and CPR—Binding
interactions betweenCPR andHO-2were also analyzed by sed-
imentation velocity ultracentrifugation, a method that is less
sensitive to heme artifacts than SPR. As described under
“Experimental Procedures,” 20.5 M CPR was titrated with
varying concentrations of heme-bound HO-2 (0–55 M). In
these experiments, the sedimentation coefficient distribution
of CPRwasmonitored in the presence of increasing concentra-
tions of hHO-2. Fig. 15A shows a sedimentation velocity profile
obtainedwith a 2:1molar ratio of hHO-2 toCPR. In the absence
FIGURE7.CPR induced changes forhHO-2 cross-peak intensitiesmapped
onto the crystal structure. The effect of 75 or 150 M CPR (A and B, respec-
tively) on hHO-2 cross-peak heights mapped on to the crystal structure of
hHO-2 (PDB2QPP). Cross-peak intensity ratios are as determined in Fig. 6. The
color of the residue reflects the degree of effect by CPR. Red indicates ratio of
0  0.2; orange indicates ratio of 0.2  0.3; blue indicates ratio  0.3; white
indicates residues that are broadened beyond detection; gray indicates resi-
dues that are unassigned.
FIGURE 8. NMR analysis of CPR binding non-perdeuterated 15N hHO-2. 1H-15N TROSY spectra of 150 M non-perdeuterated 15N-hHO-2 collected in the
absence (black) or presence (red) of equimolar CPR.
Protein/Protein Interactions Involving HemeOxygenase-2
29846 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 43•OCTOBER 24, 2014
 
of hHO-2, CPR is characterized by a sedimentation coefficient
centered at 4.5 S as shown in Fig. 15B. hHO-2 alone shows two
sedimentation coefficients with a major component (60%) cen-
tered at 2.8 S and a minor component (34%) at 4.2 S. Upon
adding hHO-2, the shape of the CPR component changes with
the boundary shifting to a higher sedimentation coefficient.
The weight-average s value of this fast boundary component
was determined by integrating the c(s) distribution between 4
and 7 S. From these data, aKd of 15.1 6.5Mwas determined
for hHO-2 and CPR. At the highest hHO-2 concentration, the
CPRHO-2 complex was characterized by a weight-average s
value of 5.2 S.
Chemical Cross-linking of CPR andHO-1 or HO-2—We con-
ducted chemical cross-linking experiments to trap the complex
between HO-2 and CPR. Because cross-linking is an irreversi-
ble reaction, even transient complexes can be detected. Because
CPR has been reported to bind HO-1 (24–27), we used HO-1
and CPR as a positive control. According to the crystal struc-
ture (PDB 3QE2), human CPR possesses at least two surface
cysteine residues, which should be available for cross-linking.
Thus, we utilized the heterobifunctional cross-linker LC-SPDP,
which contains both an amine and a thiol-reactive group. As
described under “Experimental Procedures,” after activating
HO-1 or HO-2 and removing unreacted cross-linker, CPR was
added, and the reaction was incubated overnight at 4 °C. Stable
complexes between CPR and HO-1 as well as CPR and HO-2
were formed (Fig. 16A). A small amount ofHO-2 homodimer is
visible in the HO-2 sample that lacks CPR, although, for acti-
vated HO-1 alone, no homodimeric complex was observed.
As a negative control, we activated the HOs as described
above and incubated with a physiologically unrelated cysteine-
containing protein, RNase, instead of CPR. RNase (based on
FIGURE 9. Effect of various concentrations of CPR on non-perdeuterated 15N-hHO-2 resonances. Histogram bars represent the ratio of resonance height
in the absence or presence of CPR (
CPR/CPR). Ratios with 50, 150, 200, and 300M CPR are shown (black, light gray, dark gray, andwhite bars, respectively).
A ratio of 1 (dotted line) indicates no change for that residue. Bars that are absent (gray labels) represent resonances that are unassigned, and assigned residues
are in bold. The asterisk highlights Leu-201 as the cross-peak that is most sensitive to the addition of CPR.
Protein/Protein Interactions Involving HemeOxygenase-2
OCTOBER 24, 2014•VOLUME 289•NUMBER 43 JOURNAL OF BIOLOGICAL CHEMISTRY 29847
 
 
PDB 1RCA) contains eight cysteine residues, four of which are
surface-exposed. No high molecular weight complex between
RNase A and either HO-1 or HO-2 was observed (Fig. 16B).
NMR Studies of HO-2 in the Presence of BVR—BVRmediates
the second step in heme degradation, the conversion of biliver-
din to bilirubin. HO-1 and BVR are reported to form a complex
with a Kd of 0.2 0.1 M (24, 27). An overlapping binding site
on HO-1 for CPR and BVR has been proposed but with the
binding sites not identical (24, 25, 27). To our knowledge, bind-
ing of HO-2 and BVR has not been addressed.
To attempt to characterize the binding interface between
HO-2 and BVR, we performed NMR experiments similar to
those described for HO-2 and CPR. The 1H-15N TROSY spec-
trum of 150 M non-perdeuterated 15N-hHO-2 was collected
in the absence or presence of equimolar BVR (not labeled with
15N). Although CPR induced obvious changes in the hHO-2
spectrum (Fig. 8), the spectrum of hHO-2 collected in the pres-
ence of BVR is almost identical to that of hHO-2 alone (Fig. 17).
No changes in the chemical shifts are apparent, and the major-
ity of assigned resonances exhibit a height ratio (
BVR/BVR)
close to 1, indicating no change (Fig. 18). These results suggest
that under the NMR conditions (150 M), BVR binds hHO-2
very weakly, if at all. Experiments with 15N-apoHO-2 and
equimolar BVR also showed BVR has no effect on the apoHO-2
spectrum (data not shown).
Our NMR binding studies thus suggest that BVR has a sig-
nificantly lower affinity for HO-2 compared with CPR. In con-
trast, others have reported nanomolar Kd values for the
BVRhHO-1 complex (27). Because HO-1 and HO-2 are highly
homologous, our results were unexpected. Thus, other experi-
FIGURE 10. NMR analysis of CPR binding apoHO-2. 1H-15N TROSY spectra of 500 M non-perdeuterated 15N-apoHO-2 collected in the absence (black) or
presence (red) of 100 M CPR.
FIGURE 11. TROSY spectra of hHO-2 (black) and apoHO-2 (red). 1H-15N TROSY spectra of 150 M non-perdeuterated15N-hHO-2 (black) or 500 M non-
perdeuterated apoHO-2 (red). The cross-peak assigned as Leu-201 for the hHO-2 spectrum is identified.
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ments were performed to assess the interaction between the
HOs and BVR.
Fluorescence Quenching Experiments Involving BVR-CPM
and HO-1 or HO-2—One possible explanation for the lack of
NMR evidence for an HO-2/BVR interaction is that HO-2
interacts differently with BVR compared with HO-1. To
address this possibility, we repeated the published fluorescence
quenching experiments for measuring interactions between
HO-1 and BVR (27), and we performed similar experiments to
determine the binding affinity of HO-2 for BVR. In these stud-
ies, BVR was labeled with the thiol-reactive dye CPM to pro-
duce fluorescent BVR upon excitation at 350 nm. Because the
hHO-1 absorption spectrum overlaps with the emission spec-
trum of BVR-CPM, hHO-1 binding results in fluorescence
quenching due to FRET processes. Because apoHO has no
absorbance in the 350 nm region, this method can only be used
to evaluate hHO binding. Plotting the % fluorescence quench-
ing at 455 nm versus hHO-1 concentration produced a binding
curve (Fig. 19A) that fits to a one-site bindingmodelwith aKd of
0.25  0.09 M, almost identical to the previously reported
value of 0.22  0.09 M (27). Similar FRET experiments with
hHO-2 and BVR (Fig. 19B) provided concentration-dependent,
saturable binding curves with a Kd of 0.27 0.01 M.
These results suggest that BVR binds both HO-1 and HO-2
with similar high affinity. Equation 3 can be used to estimate a
Kd value in situations where the concentration of free ligand
cannot be estimated due to high affinity and near stoichiomet-
ric binding. If HO-2 and BVR have a Kd of 300 nM (as sug-
gested by the fluorescence quenching results), Equation 3 pre-
dicts 70% of HO-2 should be complexed with BVR under the
NMR conditions (with 150 MHO-2 and 150 M BVR). This is
clearly inconsistent with the NMR results; therefore, we con-
ducted additional experiments to interrogate the source of
this apparent discrepancy between the NMR and FRET
experiments.
EL  0.5E0  L0  Kd  E0  L0  Kd
2  4E0  L0
1/ 2
(Eq. 3)
Fluorescence Quenching of BVR-CPM by Heme—To attempt
to resolve the inconsistency between the NMR and fluores-
FIGURE 12. HO mutants have an increased Km values for CPR. Heme oxy-
genase activity for HO-1 (A) or HO-2 (B) and their respective mutants with
varying amounts of CPR. Activity was monitored by observing the formation
of bilirubin at 468 nm, as described under “Experimental Procedures.”
TABLE 1
Michaelis parameters for HO variants and CPR
Heme oxygenase activity was monitored for HO-1 or HO-2 and the indicated
mutants with varying amounts of CPR as shown in Fig. 12. Specific activity is rep-
resented as nanomoles of bilirubin/min/mg of HO.
Construct Vmax Km Km
nmol min1 mg1 M -fold change
HO-1
WT 370 12 0.5 0.1 1
K149A 847 64 21.7 2.6 42.4
HO-2
WT 296.9 4.6 0.7 0.1 1
R87A 275 11 0.9 0.1 1.3
L201A 298.2 8.0 2.3 0.2 3.3
K169A 417 37 15.2 2.6 21.7
FIGURE13.HOandCPRanalysis by size exclusion chromatography.50M
CPR andHO-1 (A) or CPR andHO-2 (B) were loaded onto a Shodex KW-803 gel
filtration column individually or in the indicated mixture in the presence of
150Mhemeand150MNADP
 in runningbuffer (50mMTris, 50mMKCl, pH
7.0). Theasterisk represents the retention time for a 100-kDaprotein, and gray
arrowsmark thepositionof themolecularweight standards. Peak 1,CPR;peak
2, heme oxygenase; peak 3, NADP
 and heme; peak 4, HO-2 aggregate.
TABLE 2
Apparent molecular weight of HO-1, HO-2, and CPR by gel filtration
Ve/V0 values for the indicated proteins, blue dextran (V0), B12, and protein stan-
dards (Bio-Rad) were measured, and the apparent masses were determined as
described under “Experimental Procedures.”
Protein Ve/V0 Apparent mass
Da
HO-1 1.565 0.005 44,000 1600
HO-2 1.525 0.002 60,300 1100
CPR 1.509 0.004 68,600 2000
CPR (with HO-1) 1.507 0.004 69,600 2000
CPR (with HO-2) 1.506 0.002 70,000 1300
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cence quenching results, we tested the hypothesis that free
heme, dissociating fromHO-2, may be responsible for the fluo-
rescence quenching of BVR-CPM. When free heme was
titrated into BVR-CPM under conditions identical to those
used for hHO titrations, there was strong concentration-de-
pendent and saturable quenching of BVR-CPM fluorescence
(Fig. 19C), indicating a Kd value of 0.037  0.01 M. These
results suggest that the fluorescence quenching observed in the
FRET experiments could be due to the effects of heme binding
to BVR, or the CPM fluorophore, rather than the HO protein.
Assuming a Kd of 33 nM for HO-2 and heme (17), Equation 3
predicts that 1 M hHO-2 will contain 0.17 M dissociated
heme, which is well above the Kd value determined in these
experiments. Thus, we suggest that the quenching of BVR-
CPM fluorescence observed in the titration with hHO-1 or
hHO-2 results from free heme, dissociated from HO, not the
HO protein. We propose that the heme binds to BVR-CPM
from solution and not through direct heme transfer from the
heme-HO complex to BVR. In fact, our results demonstrate
that these proteins do not form a complex, dispelling the pos-
sibility of a protein-to-protein heme transfer.
The effects of free heme on BVR-CPM fluorescence are con-
sistent with the report that heme binds to BVR and to residues
290–296 of the BVRC-terminal peptide (KYCCSRK) (36). Fur-
thermore, when we analyzed BVR-CPM by LC MS/MS to
determine the location of the CPM label, we identified one
CPMmolecule attached to Cys-204 and another to either Cys-
292 or Cys-293 of BVR (Fig. 20). Because Cys-292 and Cys-293
are located on the same peptide in the LCMS/MS analysis, the
two cysteines were not distinguished by this analysis.
Although the other surface-exposed Cys (Cys-74) is not
observed in this analysis, it is most likely unmodified because
BVR-CPMhas enzymatic activity similar to that of thewild type
protein (109%). We and others (59) find that mutation of
Cys-74 in human BVR, or its homolog Cys-73 in rat BVR,
ablates enzymatic activity. Additionally, CPM labelingwas con-
ducted in the presence of NADP
, which is expected to protect
the enzymatic cleft from modification.
FIGURE 14. SPR analysis of CPR biding HO-1 (left panels) and HO-2 (right
panels). A, various concentrations of CPR (1.25, 2.5, 5.0, 10.0, and 20.0 M)
were injected against immobilizedHO-1 or HO-2. B, single exponential fits for
the association phase of CPR bindingHO-1 or HO-2 are shown in red. C, single
exponential fits were used to determine kobs for the association phase of CPR
binding HO-1 or HO-2. kon and koff values are derived from the linear regres-
sion of kobs (kon	 slope; koff	 y intercept).D, biexponential fits for the disso-
ciation phase of CPR binding HO-1 or HO-2 are shown in red. E, various con-
centrations of heme (0.125, 0.25, and 0.5 M) were injected against
immobilizedCPR.Data are representative of three independent experiments.
FIGURE15.SedimentationvelocityanalysisofHO-2andCPR interactions.
A, velocity scans selected from analysis of a 2:1 ratio of hHO-2 (41 M) to CPR
(20.5 M). Shown are the absorbance data (open circles) fitted (solid lines) to
the continuous c(s) distribution model. B, sedimentation coefficient distribu-
tions of CPR (20.5M) alone (black trace) and in the presence of 4.1M (brown
trace), 10.25M (blue trace), 20.5M (red trace), 30.75M (purple trace), 41M
(green trace), and 55 M HO-2 (gray trace). hHO-2 alone (41 M) is shown in
magenta. The inset shows the weight-average s value plotted versus HO-2
concentration. The datawere fit to a single-site binding isotherm to yield a Kd
value of 15.1 6.5 M.
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BVR Binding Heme by Optical Absorbance—To further
investigate the possibility that the fluorescence quenching of
BVR-CPM by hHO-2 results from the binding of free heme by
BVR, we titrated BVR with free heme and measured the absor-
bance spectrum. As observed by others (36), BVR alone shows
no optical absorbance in the 350–700 nm range; however, in
the presence of heme, we observe the development of an
absorbance band with a wavelength maximum at 415 nm, indi-
cating that free heme binds BVR (Fig. 21A). To determine the
affinity of heme for BVR, 5Mhemewas titratedwith BVR, and
the absorbance at 415 nm was measured and fit to a single-site
binding model, yielding a Kd of 220 50 nM (Fig. 21B).
Titration of BVR-CPMwith hHO-2 produces strong fluores-
cence quenching; however, because there is no evidence of
HO-2/BVR binding by NMR, we hypothesize that heme, not
HO, is responsible for a large part of the fluorescence quench-
ing. To test whether heme from hHO-2 can bind BVR, we incu-
bated hHO-2 with BVR. Because the absorbance of hHO-2 is
10-fold greater than that of heme-bound BVR and because
the absorbance spectra overlap, hHO-2 was included in the
reference cuvette for these titrations. Under these conditions,
with increasing concentrations of BVR titrated into hHO-2,
absorbance at 415 nm also increases. This result supports that
BVR is capable of binding heme from hHO-2 (Fig. 21C).
Chemical Cross-linking of HO-2 and BVR—The above results
suggest that HO-2 and BVR either do not interact or that that
they forma veryweak complex.We incubatedHO-2,whichhad
been activatedwith LC-SPDPandwithBVR, as described above
for trapping the HO-2CPR complex. Because HO-1 and BVR
have been reported to form a complex (24, 27), we also con-
ducted the experiment with HO-1 as a positive control. Under
conditions identical to those used to stabilize the HO-2CPR
complex, a high molecular mass complex of 60 kDa was
observed by SDS-PAGE for BVR and both HO-1 and HO-2
(Fig. 16C).
Because HO-2 and BVR are similar in molecular mass, a het-
erodimer of HO-2 and BVR is not distinguishable from either
homodimer by size alone. To determine whether BVR is
directly linked to HO-2 in the cross-linked product, we con-
ducted the cross-linking reaction using HO-2 that retained an
N-terminal His6 tag (hisHO-2). The cross-linked products with
hisHO-2were identical to thosewithHO-2 by SDS-PAGEanal-
ysis (data not shown). We then isolated hisHO-2 from the
cross-linking reaction using Ni-NTA resin and analyzed the
proteins that associatedwith the affinity resin by reducing SDS-
PAGE, which was subjected toWestern blotting using antibod-
ies against HO-2 or BVR. Under these conditions, the cross-
linker undergoes reduction, allowing the proteins to migrate at
their native size. BVR was found to copurify with HO-2 in the
cross-linked product (Fig. 16D). A control reaction demon-
strated that BVR alone did not associate with the affinity resin
(Fig. 16D). These results demonstrate that an HO-2BVR com-
plex can be trapped by chemical cross-linking.
To identify the location of the cross-linker in the HO-2BVR
complex, we conducted a tryptic digest followed by LC-MS/MS
analysis of the cross-linked product. This analysis identified the
HO-2 peptide containing Lys-264 (KCPFYAAEQKD) linked to
the BVR peptide containing Cys-292 and Cys-293 of BVR
(YCCSR), the same peptide shown earlier to bind heme (36).
DISCUSSION
In theHO reaction, seven electron equivalents fromNADPH
are transferred to the HO-bound heme via CPR. For rapid and
efficient electron transfer, the electron donor (flavin on CPR)
and acceptor (heme of HO-2) should be at optimal orientation
and distance, implying that an electron transfer complex is
formed during the catalytic cycle. One of the issues we have
addressed in this paper is the existence and nature of that elec-
tron transfer complex.One possibility is thatHOandCPR form
a stable complex within which multiple electrons transfer from
NADPH through the bound flavins (FAD and FMN) on CPR to
the HO-bound heme as it undergoes oxygenation and conver-
sion to biliverdin and CO. The other possibility is that HO and
CPR encounter each other only transiently and associate/disso-
ciatemultiple times during each catalytic cycle. Similarly, either
HO or BVR forms a stable complex, within which biliverdin is
transferred (perhaps channeled) between the two proteins or,
as another alternative, remains completely unattached as the
HO product (biliverdin) is released into solution and captured
FIGURE 16. Chemical cross-linking of HO-2 and CPR. A, heterobifunctional
cross-linker LC-SPDP stabilizes a complex between HO-1 or HO-2 and CPR. B,
no complex is trapped for HO-1 or HO-2with RNase. C, chemical cross-linking
also stabilizes a complex between HO-1 or HO-2 and BVR. Cross-linking reac-
tions contained 10 M of the indicated protein. D, reducing SDS-PAGE and
Westernblot ofHO-2pulldownandassociatedBVR. Lane1, cross-linking reac-
tion; lane 2, HO-2 only; lane 3, BVR only.
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by BVR to undergo conversion to bilirubin. Based on fluores-
cence quenching, SPR and acetylation protection studies, a
moderately tight HO-1CPR complex with a Kd value in the1
M range had been identified. However, SPR, fluorescence
quenching, and acetylation protection assays with HO-1 have
yielded inconsistent results regarding which residues form the
HO-1/CPR binding interface (24, 25, 27).
Interactions between HO and CPR—Whether or not HO-2
and CPR form a complex has not been previously investigated.
As a result of spectroscopic (NMR, fluorescence), steady-state
kinetic, and other biochemical (chromatographic, analytical
centrifugation, and SPR) studies, we have obtained novel infor-
mation about the nature of the interactions between these two
proteins.
Although our focus is on HO-2, we also analyzed CPR bind-
ing to HO-1, primarily as a positive control for the HO-2/CPR
studies, as CPR binding HO-1 has been previously described
(24–27). Consistent with previous reports, we observe CPR
binding HO-1 by SPR and by chemical cross-linking.
By gel filtration experiments, under our experimental condi-
tions (50MhHOand 50MCPRwithNADP
), HO-2 appears
to form a homodimer. We do not observe any evidence for a
complex between HO-2 and CPR. Gel filtration experiments
occur under nonequilibrium conditions in which the compo-
nent proteins of any transient complex, once dissociated from
the complex, are unable to reassociate once they are in a
separate zone of the chromatographic column. However,
SPR experiments clearly demonstrate CPR binding to HO-2
(Fig. 14).
SPR is a valuable method for studying protein-protein inter-
actions because the proteins remain in the same solution and
reach equilibrium; furthermore, one canmonitor both the rates
of association and dissociation. Our SPR results clearly demon-
strate that CPR binds to both HO-1 (Kd	 20.5 M) and HO-2
(Kd 	 16.7 M) with CPR-dependent rates of association and
CPR-independent dissociation rates. ForHO-1, our results give
a Kd value that is 10-fold larger than previously reported (24).
The lower affinity of CPR for HO-1 observed in our studies
could be due to differences in the experimental design; our
studies were conducted in the absence of heme and utilized
immobilized HO-1 with human CPR as the soluble analyte,
whereas earlier studies were conducted with immobilized rat
CPR with hHO-1 in solution. Although we also observe a bind-
ing response when we titrate either hHO-1 or hHO-2 against
immobilized human CPR, we found that free heme also pro-
duces a strong binding response with immobilized human CPR
(Fig. 14E) and with immobilized BVR (data not shown). Thus,
to avoid potential artifacts, these experiments were performed
in the absence of heme. Our use of the apo-HOs is justified by
our NMR experiments, which clearly demonstrate that CPR
can bind both forms (apoHO-2 and heme-bound) of HO-2.We
are unaware of any physiologic rationale for heme binding to
CPR, so this is likely to be a nonspecific effect. However, as we
discuss below, BVR has previously been shown to bind heme
and to shuttle heme into the nucleus (36). Although by SPR we
observe no binding of apoHO to immobilized CPR, the confor-
mation of CPR is critical for HO binding (26), and it is possible
that immobilization of CPR stabilizes a conformation that has a
lower affinity for HO.
Sedimentation velocity experiments also provide evidence of
a dynamic complex between HO-2 and CPR, with a Kd (15.1
M) value that is similar to that calculated from the SPR data.
The HO-2CPR complex can also be captured by chemically
cross-linking an amino group of HO-2 through a 15.7 Å tether
to a surface-reactive Cys residue on CPR. The latter is, of
FIGURE 17.NMR analysis of BVR binding HO-2. 1H-15N TROSY spectra of 150M non-perdeuterated 15N-hHO-2 collected in the absence (black) or presence
(red) of equimolar BVR.
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course, irreversible and designed to capture even highly tran-
sient interactions.
The NMR experiments also show that an interaction
between HO-2 and CPR occurs. The primary proof is the over-
all and large loss of peak intensity for the core resonances, due
to broadening associated with the large increase in time-aver-
aged molecular weight. In addition, excess peak intensity loss
due to exchange broadening and CSP occurs for several but not
all signals. The latter observations are compatible with specific
binding and with binding kinetics that are on the fast/interme-
diate NMR shift time scale (koff100 s1). In turn, this is sug-
gestive of a Kd value in the low micromolar range, consistent
with the values of 15 M as found by analytical ultracentrifuga-
tion experiments and 16.7 M as found by SPR. Regretfully, the
NMR experiments do not allow a precise determination of
these values, because theNMR signals disappear at higher titra-
tion stoichiometries, and saturation of binding cannot be
observed.
Having assigned70% of the resonances in the HO-2 NMR
spectrum, we used the CSPs to identify the HO-2/CPR inter-
face. Titration of perdeuterated 15N-hHO-2 with CPR altered
the chemical shift of several residues in the hHO-2 NMR spec-
trum. At both 75 and 150 M CPR, residues of the HO-2 cata-
lytic core exhibit larger CSPs compared with the N and C ter-
mini (Fig. 4). Residues that exhibit the largest CSPs with the
addition of 75 M CPR are Phe-99, Tyr-202, Leu-66, Lys-89,
and Glu-190.
Upon adding CPR, we also observed dramatic and titratable
reductions in the intensities of some of the 1H-15N TROSY
peaks of resonances from the catalytic core domain of HO-2
(Figs. 6 and 9). The majority of intensity changes due to
exchange broadening of the TROSY peaks occur in the struc-
FIGURE 18.Effect of BVRonHO-2 resonances. The ratio of hHO-2 resonance heightwith andwithout equimolar BVR (
BVR/BVR) is representedby the gray
bars. A ratio of 1 (dashed line) indicates no change for that residue. Bars that are absent (gray labels) represent resonances that are unassigned, and assigned
residues are in bold.
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tured core region of HO-2, with few intensity changes originat-
ing from the dynamically unfolded N (Ser-8) or C terminus
(Tyr-268). Chemical shift perturbations induced by CPR titra-
tions also affect the core residues of hHO-2, although theN and
C termini are unaffected (Fig. 4). These results indicate that
CPR interacts with the catalytic core of the protein and has
minimal interactions with the N- or C-terminal regions of
HO-2.
Fig. 22A highlights residues on hHO-2 that exhibit both sig-
nificant CSPs and large intensity changes with the addition of
75 M CPR as follows: Leu-66, Phe-99, Glu-102, Asp-193, Gln-
200, Tyr-202, and Leu-209. Strikingly, in the recent HO-1/CPR
crystal structure, residues conserved with HO-2, Phe-99, Glu-
102, Gln-200, and Tyr-202 form a patch that is at the CPR
interface (Fig. 22B). TheHO-1 residue conserved with Asp-193
is also located at the CPR interface, as are HO-1 residues con-
served with the HO-2 residues targeted by mutagenesis, Leu-
201 and Lys-169 (Fig. 22).
Additional HO-2 residues show either significant CSPswith-
out extra intensity change or large changes in intensity without
chemical shift changes. Especially the latter phenomenon is
prevalent for the most affected residue, Leu-201, and is theo-
retically incompatible with a canonical intermediate exchange
binding process as described by Equation 2. Rather, it is sugges-
tive of additional, significantly populated bound states of CPR
sensed by Leu-201 that are in intermediate/fast exchange with
each other and with Leu-201 in the free state. It can be shown
that the observed broadening without shift can occur if the
CSPs of the different bound states approximately cancel.6 The
residues affected by this noncanonical mechanism are con-
served in HO-1, where they are located at the interface for CPR
6 E. R. P. Zuiderweg, unpublished data.
FIGURE 19. Fluorescence quenching of BVR-CPM by heme oxygenases
andheme.Titrationofheme-boundHO-1 (A), HO-2 (B), or hemealone (C) into
BVR-CPM. Percent fluorescencequenchingplotted against the concentration
of the titrant and fit to a single bindingmodel to determine the Kd of binding
using GraphPad Prism 6.0.
FIGURE 20. Biliverdin reductase modified by CPM. LC-MS/MS analysis of
BVR-CPM identifies CPM modification (*) at Cys-280 and either Cys-292 or
Cys-293. Cys-74 was not observed in this analysis.
FIGURE 21. Heme binds BVR by optical absorbance. A, absorbance spec-
trum of 2.5M BVRwith 2.0M heme. BVR alone shows no absorbance in the
350–700 nm range. B, A414 of 10 M heme titrated with varying concentra-
tions of BVR (0.05, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.2, 2.0, 3.0, and 5.0 M BVR). Data
are fit to a single binding model using GraphPad Prism 6.0. C, 5 M hHO-2
alone (dotted line) or titrated with various concentrations of BVR (1.0, 2.0, 8.0,
10.0, and 20.0 M). Samples for BVR titrations contain 5 M hHO-2 in the
reference cuvette because the absorbance of hHO-2 is 10-fold that of
heme-BVR, and thehHO-2 spectrumoverwhelms theheme-BVR spectrum if it
is not subtracted.
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(Glu-86,Asp-90,Glu-190, Leu-201,Arg-203,Ala-208, andAsp-
210) or in patches of residues adjacent to the interface in (Ala-
31, Leu-33, Leu-36, Leu-37, Leu-81, Glu-107, Lys-89, Asn-88,
Leu-149, Gln-172, Glu-182, Thr-184, and Thr-215). These res-
idues also localize at and around the binding site for HO-2 as
identified from CSPs alone. The extended nature of the inter-
action surface would also be compatible with multiple binding
modes for CPR as implied from the noncanonical broadening.
The existence of multiple bound states, or an ensemble of
encounter complexes, has been suggested for other electron
transfer complexes as well (60, 61).
NMR relaxation and gel filtration studies indicate that HO-2
exists as a homodimer in solution at the conditions used.
Changes in the homodimerization state of HO-2 upon CPR
binding could give rise to CPR-dependent changes in the
TROSY spectrum, and these changes would be difficult to dis-
tinguish from changes induced by CPR binding HO-2 directly.
However, HO-2 crystallizes as a homodimer, and the HO-2/
HO-2 interface is distant from themajority of the CPR-induced
changes that occur in the HO-2 TROSY spectrum (Fig. 22A).
This supports that the CPR-induced changes observed in the
HO-2 TROSY spectrum are not due to changes in the HO-2
dimerization state but rather CPR directly binding to HO-2.
There is a major difference between the koff as suggested by
NMR (100 s1) and the value measured by SPR (0.023 s1).
The latter value would give rise to an extremely slowNMR shift
time scale andwould not allow for any of the observed chemical
shift changes. This contradictory situation is reminiscent of the
binding of an organic phosphate molecule to hemoglobin,
where, despite an off-rate of 0.01 s1, fast exchange dynamics
were observed using 31P NMR. Multiple binding sites for the
small molecule on the hemoglobin surface were proposed to
explain the apparent discrepancy, and a mathematical model
that recapitulated the experimental results was described (62,
63). In this study, we have evidence for the existence ofmultiple
bound states of CPR. Perhaps the observed rate of100 s1 as
indicated byNMR is reflective of the exchange kinetics between
the various bound states. In contrast, the off-rate as measured
by SPR monitors the complete dissociation.
Although previous reports on the HO-1CPR complex focus
on charge-charge interactions (from residues that we were not
able to assign in our NMR spectra), our results provide the
first evidence that hydrophobic residues may be involved in
HO/CPR binding. The majority of the residues highlighted in
the NMR binding studies are involved in interacting with the
FAD binding domain of CPR (Fig. 22). Kinetic results discussed
below concur with these NMR results.
Our steady-state kinetic analyses support the conclusion that
the area near the exposed heme binding face in the catalytic
core of HO-2 is involved in binding CPR. For example, HO-1
and HO-2, which share a high degree of structural similarity in
their catalytic core region (55), exhibit similar Km values for
FIGURE 22. Interface for CPRonHO-2 definedbyNMRandmutagenesis. A, residues in red have both significant CSPs and large intensity ratio changeswith
the addition of 75 M CPR. Residues of HO-2 that have significant CSPs or large changes in peak intensity ratio with the addition of 75 M CPR are shown in
orange. { identifies a patch of residues strongly affected by CPR (Phe-99, Glu-102, Gln-200, Leu-201, and Tyr-202). Leu-201 and Lys-169 were identified by
mutagenesis. Side chains are shownas spheres (PDB2QPP).B, residues identified forHO-2mappedonto theanalogous residuesofHO-1 in thepublishedcrystal
structure of the complex of rat HO-1 (gray) and rat CPRTGEE (yellow) (PDB 3WKT). Cofactors are as indicated as follows: heme (green), NADP
 (blue), FAD
(purple), and FMN (orange).
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CPR (0.5–0.7 M). Furthermore, alanine substitution of the
core residues that are proposed to be at the HO/CPR interface,
Lys-169 (or Lys-149 in HO-1) and Leu-201, results in signifi-
cant increases in the Km value for CPR. K169A, for example,
exhibits a 20-fold increase in Km for CPR, in close agreement
with prior SPR (24) and acetylation protection assays (25) but in
contrast with earlier FRET measurements, which showed no
effect of Ala substitution at that site (27). The K169A variant of
HO-2 also exhibits a 1.4-fold increase in Vmax, and the K149A
variant of HO-1 exhibits a 2.2-fold increase in Vmax suggesting
that lowering the affinity forCPR increases the steady-state rate
under saturating substrate (NADPH, O2, and CPR) concentra-
tions. That theK149Avariant binds hemewith identical affinity
as the wild type (24) and does not exhibit a decrease (instead a
slight increase) in Vmax supports our conclusion that its
increase in Km for CPR reflects disruption of a key interaction
between CPR and HO-2, not some major disruption in the
overall structure or at the active site.
The HO reaction involves many steps, including heme bind-
ing, seven steps of electron transfer, 3 mol of oxygen binding,
oxygen activation, biliverdin release, etc. It is accepted that the
rate-limiting step in theHO-1 catalytic cycle when BVR is pres-
ent is the ring opening of Fe(II)-verdoheme (40, 64).However, it
is possible that this lysine variant is rate-limited by another step.
The details of the catalytic cycle for HO-2 or for this variant
have not been characterized. However, given that K149A
(HO-1) and K169A (HO-2) exhibit a 1.4–2.2-fold increase in
Vmax and a 20–40-fold increase inKm for CPR, it seems reason-
able to speculate that, at saturating concentrations of CPR, the
rate-limiting step for this lysine variant is electron transfer from
CPR to the heme.
Taken together, our results suggest that during themultistep
HO-2 reaction, a transient complex between HO-2 and CPR
forms and dissociates rapidly and that the productive electron
transfer complex includesHO-2 residues Leu-201 and Lys-169.
The transient nature of the interactions between HO-2 and
CPR is likely to be an important catalytic feature, especially in
this and other systemswheremultiple electronsmust be passed
during each catalytic cycle.
Our results indicate that a similar dynamic and transient
binding scenario exists with HO-1. Our gel filtration and SPR
results indicate that HO-1 (like HO-2) forms a rather weak
complex with CPR. The transient nature of these interactions
betweenHOandCPR is likely to be important in theHOmech-
anism, which requires seven electrons to be transferred from
NADPH through the redox centers on CPR.
The catalytic core, shown clearly to be the domain of HO-2
that interacts with CPR, is highly homologous with HO-1. For
example, catalytic core residues with NMR resonances most
strongly affected by CPR that exhibit both CSPs and broaden-
ing (Leu-66, Phe-99, Glu-102, Asp-193, Gln-200, Tyr-202, and
Leu-209) or with binding constants affected by mutagenesis
(Lys-169 and Leu-201) are highly conserved betweenHO-1 and
HO-2.All of those residues are strictly conserved except Leu-66
(Gly-46 in HO-1). Earlier reports identified Lys-149 of HO-1 to
be important in binding CPR (24, 25). It was shown that CPR
prevents acetylation of that Lys residue and that substitution of
Ala at that position results in a 7-fold decrease in affinity for
CPR.We found that the K149A substitution results in a 40-fold
increase inKm for CPR (20-fold for the analogous K169Amuta-
tion inHO-2). Thus, it appears that bothHOs interact similarly
with CPR.
Our results support that HO-2 forms a highly dynamic com-
plex with CPR at an interface that includes HO-2 residues Leu-
201 and Lys-169, and the CPR interface is likely highly con-
served for both HO-1 and HO-2. As shown in Fig. 22B, the
homologous residues in HO-1 (Leu-181 and Lys-149) are
located at the HO-1/CPR interface in the crystal structure of a
complex between HO-1 and a deletion variant of CPR (CPR
TGEE) (26). This CPR variant forms a stable complex with
HO-1 that, unlike the wild type protein, can be observed even
by gel filtration (26). Given the high homology of the structures
of the catalytic cores of HO-1 and HO-2 (55), we suggest that
Leu-201 andLys-169 ofHO-2 participate in stabilizing the elec-
tron transfer complex between HO-2 and CPR.
Interactions between HO and BVR—Based on prior fluores-
cence quenching studies, HO-1 and BVR were proposed to
form a high affinity complex (27), and our goal was to charac-
terize the analogous HO-2BVR complex using various bio-
chemical and biophysical methods. However, addition of BVR
to 15N-labeled hHO-2 results in no chemical shift perturbation
and, of the 104 assigned resonances in the hHO-2 spectrum,
only five exhibit a BVR-dependent decrease in intensity. Of
those residues that exhibit sensitivity to BVR, three are on the
surface of the crystal structure and could reasonably be
involved in binding BVR (Lys-176, Gln-196, and Tyr-229) (Fig.
18). In contrast, under the same conditions with equimolar
CPR, 48 of the assigned HO-2 resonances exhibit strong CPR-
dependent effects (Fig. 9). These results suggest BVR binds
hHO-2 with a weak affinity compared with CPR.
Because the TROSY experiments indicated that HO-2 does
not bind BVR with high affinity (Fig. 18), we repeated the orig-
inal fluorescence quenching studies that described the hHO-
1BVR complex (27). Although our results with hHO-1 are
nearly identical to those described in the original paper, addi-
tional controls indicate that free heme strongly quenches BVR-
CPM fluorescence independently of HO. We also used optical
absorbance methods to verify the ability of BVR to bind heme,
as was reported previously (36). TheKd value for the hemeBVR
complex differs between the two experiments, with the absor-
bance data indicating binding of more than heme to BVR. Fur-
thermore, labeled BVR contains fluorophores at two specific
sites (Cys-292 or Cys-293 and Cys-204). We suggest that the
fluorescence quenching studies may monitor binding of one
heme to BVR at a high affinity site near one of these fluoro-
phores, although the optical absorbance studies may reflect
multiple heme binding events.
Thus, the fluorescence quenching studies aimed at studying
interactions betweenHO-2 and BVR actually report on binding
of heme in solution that has dissociated from hHO, rather than
direct interactions between hHO and BVR. In fact, detection of
an HOBVR complex requires the use of methods like chemical
cross-linking, where even transient complexes can be trapped.
This result describing the low affinity of HO for BVR is
important because it clarifies the mechanism by which BVR
couples to the HO reaction. It has been shown that BVR
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changes the rate-limiting step of the HO-1 reaction from biliv-
erdin release to the conversion of the Fe2
-verdoheme inter-
mediate to Fe3
-biliverdin (40). We had taken this to indicate
the possibility that biliverdin is channeled between the two pro-
teins. However, it now appears that the effect of BVRon theHO
rate-limiting step occurs by kinetic coupling of the HO and
BVR reactions, not substrate channeling. BVR binds HO-2 very
weakly; therefore, substrate channeling, which requires a stable
complex, is unlikely. Thus, BVR simply binds the biliverdin
upon release from its product complex withHO, enhancing the
HO reaction by affecting the mass balance.
Conclusions—In conclusion, we show that proteinprotein
complexes between HO-2 and other proteins in the heme deg-
radation pathway (CPR and BVR) are highly transient. HO-2
and CPR form a transient electron transfer complex and, like
other electron transfer pairs, HO-2 and CPR may form an
ensemble of complexes that is in equilibrium with the produc-
tive electron transfer complex. NMR binding studies and
mutagenesis of HO-2 highlight an interface for CPR on HO-2,
which is consistent with what has been described for CPR and
HO-1. However, in contrast to studies with CPR andHO-1, our
results suggest that CPR binding HO-2 in solution is dynamic.
Gel filtration and ultracentrifugation studies support a weak/
transient CPRHO-2 complex. Complex formation between
HO-2 and BVR is undetected, except via irreversible binding
(cross-linking) methods. In the cell, CPR is an electron donor
for many biologically important reactions. The dynamic inter-
actions between CPR and HO-2 revealed in these studies may
play an important role in the regulation of the HO system in a
cellular context.
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